Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Vivet Therapeutics logo — Vivet Therapeutics develops gene therapy treatments for inhe...

Vivet Therapeutics

Vivet Therapeutics develops gene therapy treatments for inherited liver disorders using liver tropic virus.

Founded 2016 France France 16 employees Grant Total: $87.40M Biopharma, Biotechnology +1

General Information

Company Name Vivet Therapeutics
Founded Year 2016
Location France France
Employees 16
Industries Biopharma, Biotechnology, Health Care
Funding Stage Grant
Business Model B2B, B2D
Revenue Model Licensing, Performance Based, Project Based
Social

BounceWatch is an independent company data service, not affiliated with Vivet Therapeutics. To contact Vivet Therapeutics, visit vivet-therapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Vivet Therapeutics compare?

A PDF of Vivet Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Vivet Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Vivet Therapeutics

Vivet Therapeutics is a pioneering company within the Biopharma and Biotechnology industries, solidifying its focus on advancing innovative gene therapy treatments specifically for inherited liver disorders. Established in 2016, the company has positioned itself as a leader in treating orphan diseases using the proprietary technology of liver tropic virus.

Partnering with Fundacion para la Investigacion Medica Aplicada (CIMA, Universidad de Navarra), Vivet Therapeutics is strategically optimizing gene delivery systems through the development of novel AAV vectors to target liver conditions more effectively. This collaborative effort establishes them as vanguards in healthcare innovation based in France.

Recently, the startup secured a significant €4.90M Grant invested by France 2030 as of 01 February 2024. This investment underscores confidence in the company's mission and its potential to address unmet needs in health care, particularly within the niche of genetic liver disorders.

Business keywords: Gene Therapy, Inherited Liver Disorders, Orphan Diseases, Liver Tropic Virus, AAV Vectors, Liver Targeting, Gene Delivery Optimization, Long-term Expression, Collaborative Research, Biotechnology Innovation, Medical Research Partnership

Services & Products

Development of transformative gene therapies
AAV-based therapeutic technologies
Research and clinical trials focused on rare diseases
Patient advocacy and support in rare genetic disorders

Target Customers

Patients with rare genetic disorders Healthcare professionals in gene therapy Biotechnology partners Investors in healthcare and biotechnology sectors

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Grant €4.90M 1
France 2030
01 Feb 2024
Corporate Round €45.00M 1
Pfizer
20 Mar 2019
Series A €37.50M 6
Kurma Partners Novartis Venture Fund HealthCap
Kurma Partners, Novartis Venture Fund +4
04 May 2017
Seed Round Undisclosed 1
Euazeo
Euazeo
01 Apr 2017

Vivet Therapeutics Alternatives & Competitors

View All Alternatives
Vivet Therapeutics vs
REGENXBIO
REGENXBIO United States

Seeking to improve lives through the curative potential of gene therapy.

IPO
389 employees
Biopharma, Biotechnology
Compare Vivet Therapeutics vs REGENXBIO
Vivet Therapeutics vs
Spur Therapeutics
Spur Therapeutics United Kingdom

Toward the next generation of gene therapy.

Post-IPO Equity
122 employees
Biopharma, Biotechnology
Vivet Therapeutics vs
AAVantgarde
AAVantgarde

Pioneering treatments for Stargardt disease and Usher 1B, addressing the root cause of the disease

Series A
70 employees
Biotechnology, Health Care
Also compare with: Vivet Therapeutics vs Portola Pharmaceuticals Portola Pharmaceuticals View all alternatives

FAQ About Vivet Therapeutics

Vivet Therapeutics develops gene therapy treatments for inherited liver disorders using liver tropic virus.
Vivet Therapeutics was founded in 2016.
Vivet Therapeutics is headquartered in France.
Vivet Therapeutics operates in Biopharma, Biotechnology and Health Care. Its work centres on Gene Therapy, Inherited Liver Disorders, Orphan Diseases and Liver Tropic Virus. Its customers include Patients with rare genetic disorders, Healthcare professionals in gene therapy and Biotechnology partners.
Vivet Therapeutics has a B2B and B2D business model. Its revenue comes from Licensing, Performance Based and Project Based.
Vivet Therapeutics has approximately 16 employees.
Vivet Therapeutics has completed 4 funding rounds, raising a total of $87.40M. The latest funding stage is Grant.
Vivet Therapeutics offers: Development of transformative gene therapies, AAV-based therapeutic technologies, Research and clinical trials focused on rare diseases, Patient advocacy and support in rare genetic disorders.
Top alternatives and competitors to Vivet Therapeutics include REGENXBIO, Spur Therapeutics, AAVantgarde, 克睿基因 Cure Genetics, Ultragenyx. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Vivet Therapeutics and REGENXBIO are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Vivet Therapeutics, https://bouncewatch.com/company/vivet-therapeutics, updated 11 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout